“The global burden of cancer is devastating. There were 18.1 million new cases of cancer in 2018 and half of them were in Asia. There were more than 5.4 million cancer deaths in Asia, which accounted for 60% of global cancer mortality.” “Guardant Health recognized this problem and developed a diagnostic solution for the entire continuum of cancer from advanced stage to early detection. Our proprietary blood test or liquid biopsy, the Guardant360^®, is safe, quick and non-invasive. It has a fast turnaround time of 7 days and can be used for treatment selection for advanced cancers.